BIOCRYST PHARMACEUTICALS INC — Board/Management Information 2021

Aug 26, 2021

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 24, 2021

---

BioCryst Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

---

Delaware	000-23186	62-1413174
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

Postal Address Country=

4505 Emperor Blvd., Suite 200

Durham , North Carolina 27703

(Address of Principal Executive Offices) (Zip Code)

Phone Number

( 919 ) 859-1302

(Registrant's telephone number, including area code)

Former Name

(Former name or former address, if changed since last report)

---

Checkboxes

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Table

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	BCRX	Nasdaq Global Select Market

Emerging Growth Company

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

8-K Items

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 24, 2021, the Board of Directors (the “Board”) of BioCryst Pharmaceuticals, Inc. (the “Company”) voted to increase the size of the Board from nine directors to ten directors and elected Steven Galson, M.D. to fill the vacancy created by the enlargement of the Board, effective September 1, 2021 (the “Effective Date”). Dr. Galson’s initial term will expire at the Company’s annual meeting of stockholders in 2022.

The Board also appointed Dr. Galson to serve on the Science Committee, effective as of the Effective Date.

Pursuant to the Company’s Stock Incentive Plan, Dr. Galson will receive an automatic grant of 60,000 stock options upon joining the Board and will be entitled to a grant of 40,000 stock options after each annual stockholders’ meeting, subject to continued Board service. Dr. Galson will receive compensation consistent with the Company’s director compensation policy as described in the Company’s proxy statement for its 2021 annual meeting of stockholders.

On August 26, 2021, the Company issued a press release announcing the addition of Dr. Galson to the Board. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release dated August 26, 2021 entitled “BioCryst Appoints Dr. Steven Galson to Board of Directors”
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

Signatures

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ Alane Barnes
Alane Barnes
Chief Legal Officer

Exhibit Index

(919) 859-1302 Form 8-KAugust 26, 2021